Back to News
Market Impact: 0.15
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Source: fool.com
Company FundamentalsCapital Returns (Dividends / Buybacks)Patents & Intellectual PropertyHealthcare & Biotech
Bristol Myers Squibb yields 4%, versus a 1.4% average for pharmaceutical stocks. The company is navigating a transition as older drugs lose patent protection, creating a headwind alongside its higher dividend yield.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.10
More News
- Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Decisive election. Dramatic stock swings. How we handled the market last week
- Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline
- Berkshire shares surge as Wall Street swoons amid AI fears
- Paraguay’s ousted president charged over banking scandal